Accurate Investment Solutions Inc. Acquires 1,529 Shares of Johnson & Johnson (JNJ)
Accurate Investment Solutions Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 5.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,266 shares of the company’s stock after buying an additional 1,529 shares during the period. Johnson & Johnson accounts for about 2.9% of Accurate Investment Solutions Inc.’s portfolio, making the stock its 12th largest holding. Accurate Investment Solutions Inc.’s holdings in Johnson & Johnson were worth $3,915,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Stelac Advisory Services LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $108,000. Financial Gravity Wealth Inc. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $105,000. Princeton Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $141,000. Smart Portfolios LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $150,000. Finally, Fenimore Asset Management Inc. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $217,000. Hedge funds and other institutional investors own 66.62% of the company’s stock.
NYSE JNJ opened at $142.88 on Monday. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $383.33 billion, a price-to-earnings ratio of 19.57, a price-to-earnings-growth ratio of 2.27 and a beta of 0.69. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.32.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.
Several research analysts have recently weighed in on the stock. Wells Fargo & Co restated an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, July 15th. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, June 12th. Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price for the company. Finally, ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $142.87.
In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Call Option
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.